There was some choice reading in the bmj recently: ‘Editor’s Choice – Breast screening controversy continues’ Fiona Godlee, editor, (BMJ 2013;346:f477) in which she flags up calls for more honest information on the harms of screening (BMJ 2010;340:c3106, BMJ 2011;343:d6894); the Marmot committee report summarised by Nigel Hawkes at the time (BMJ 2012;345:e7330); Michael Baum’s article (below) (doi:10.1136/bmj.f385) which criticizes the Marmot report because its estimates of harms ‘was based on three old and shortish randomised trials, and the analysis takes no account of the improvements in treatment since these trials were done, which will reduce the benefits of screening. Nor does it make use of more recent observational data. With these data included, estimated rates of overdiagnosis as a result of screening increase to up to 50%.’; and Jolyn Hersch and colleagues’ paper which looks at women’s attitudes to screening and ‘overdiagnosis’ (doi:10.1136/bmj.f158) – commenting ‘Attitudes might also harden if we were less coy about what we mean by overdiagnosis. In almost all cases of screen detected breast cancer, overdiagnosis means overtreatment.’
‘…Screening reduces breast cancer mortality. But for every death prevented three women will have their breast unnecessarily removed or irradiated. The radiation will cause at least as many other deaths from lung cancer and heart attacks as the screening prevented. Maybe more. Still want it?... Baum is professor emeritus of surgery at University College London, was chief investigator of many key breast cancer trials, and knows what he’s talking about.’
(If a cancer is found by screening when there are no symptoms it is described by patients and screening enthusiasts as having been found ‘early’ and patients claim the early finding ‘saved my life’. But no-one can know how long it had been there. And this ‘early’ finding can simply extend the time a person is a diagnosed cancer patient; the time from diagnosis to death is longer than it would have been if the cancer had been found later when symptomatic. So, this does not show screening saves lives, it only appears to. This explanation is not as comforting or welcome as ‘screening saves lives’ so is often ignored.) “This point has been made many times before. But the message has not yet reached every doctor.”
BMJ 2013;346:f548
http://www.bmj.com/content/346/bmj.f548?etoc=
Rich reading from rapid responses
A recent rapid response to Professor Michael Baum’s bmj article ‘Harms from breast cancer screening outweigh benefits if death caused by treatment is included’ (http://www.bmj.com/content/346/bmj.f385)- by Owen P Dempsey GP (Manchester Metropolitan University) – is an interesting and original approach which exposes much of what is wrong with the push for screening to continue and flags up ‘compelling contradictions in the discourse of the UKBCSP’.
Following Professor Sir Mike Richards’ comments that most UK ‘experts’ didn’t ‘trust’ the findings of the Nordic Cochrane review by Gotzsche et al, ‘such comments have remained unsubstantiated by any published evidence according to McPherson who alleges he was quietly told to cease asking for citations to support these claims by the mysterious UK experts. But, and here is the first puzzle, why would the Cochrane review not be ‘trusted’, and why would there be calls for a UK government and breast cancer charity sponsored so-called ‘independent’ review when a Cochrane review had just been published?’
http://www.bmj.com/content/346/bmj.f385?tab=responses
Whatever cancer throws your way, we’re right there with you.
We’re here to provide physical, financial and emotional support.
© Macmillan Cancer Support 2024 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007